BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014;74:563-578. [PMID: 24671907 DOI: 10.1007/s40265-014-0197-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Seifert R, Schneider EH, Bähre H. From canonical to non-canonical cyclic nucleotides as second messengers: pharmacological implications. Pharmacol Ther 2015;148:154-84. [PMID: 25527911 DOI: 10.1016/j.pharmthera.2014.12.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
2 Silveira MM, Adams WK, Morena M, Hill MN, Winstanley CA. Δ9-Tetrahydrocannabinol decreases willingness to exert cognitive effort in male rats. J Psychiatry Neurosci 2017;42:131-8. [PMID: 28245177 [PMID: 28245177 DOI: 10.1503/jpn.150363] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
3 Squintani G, Donato F, Turri M, Deotto L, Teatini F, Moretto G, Erro R. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray. J Neurol Sci 2016;370:263-8. [PMID: 27772772 DOI: 10.1016/j.jns.2016.09.054] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
4 Moreno Torres I, Sanchez AJ, Garcia-Merino A. Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis. Expert Rev Neurother 2014;14:1243-50. [PMID: 25331416 DOI: 10.1586/14737175.2014.971758] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
5 Baron EP. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache 2018;58:1139-86. [PMID: 30152161 DOI: 10.1111/head.13345] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 31.5] [Reference Citation Analysis]
6 Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO. Training and Practices of Cannabis Dispensary Staff. Cannabis Cannabinoid Res 2016;1:244-51. [PMID: 28861496 DOI: 10.1089/can.2016.0024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 28] [Article Influence: 9.8] [Reference Citation Analysis]
7 McCoy KL. Interaction between Cannabinoid System and Toll-Like Receptors Controls Inflammation. Mediators Inflamm 2016;2016:5831315. [PMID: 27597805 DOI: 10.1155/2016/5831315] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
8 Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 2016;9:9-30. [PMID: 26788128 DOI: 10.1177/1756285615612659] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
9 García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules 2020;10:E1575. [PMID: 33228239 DOI: 10.3390/biom10111575] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 18.0] [Reference Citation Analysis]
10 Russo M, Rifici C, Sessa E, D'Aleo G, Bramanti P, Calabrò RS. Sativex-induced neurobehavioral effects: causal or concausal? A practical advice! Daru 2015;23:25. [PMID: 25881038 DOI: 10.1186/s40199-015-0109-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Greydanus DE, Kaplan G, Baxter LE, Patel DR, Feucht CL. Cannabis: The never-ending, nefarious nepenthe of the 21st century: What should the clinician know? Disease-a-Month 2015;61:118-75. [DOI: 10.1016/j.disamonth.2015.01.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
12 Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry 2019;41:9-14. [PMID: 30328956 DOI: 10.1590/1516-4446-2017-0015] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 18.7] [Reference Citation Analysis]
13 Russo M, Calabrò RS, Naro A, Sessa E, Rifici C, D'Aleo G, Leo A, De Luca R, Quartarone A, Bramanti P. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast 2015;2015:656582. [PMID: 25699191 DOI: 10.1155/2015/656582] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
14 Contin M, Mancinelli L, Perrone A, Sabattini L, Mohamed S, Scandellari C, Foschi M, Vacchiano V, Lugaresi A, Riva R. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. Clin Neuropharmacol 2018;41:171-6. [PMID: 30024443 DOI: 10.1097/WNF.0000000000000294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Metz TD, Borgelt LM. Marijuana Use in Pregnancy and While Breastfeeding. Obstet Gynecol 2018;132:1198-210. [PMID: 30234728 DOI: 10.1097/AOG.0000000000002878] [Cited by in Crossref: 52] [Cited by in F6Publishing: 12] [Article Influence: 26.0] [Reference Citation Analysis]
16 Baron EP, Lucas P, Eades J, Hogue O. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J Headache Pain 2018;19:37. [PMID: 29797104 DOI: 10.1186/s10194-018-0862-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 20.3] [Reference Citation Analysis]
17 Braun M, Khan ZT, Khan MB, Kumar M, Ward A, Achyut BR, Arbab AS, Hess DC, Hoda MN, Baban B, Dhandapani KM, Vaibhav K. Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization. Brain Behav Immun 2018;68:224-37. [PMID: 29079445 DOI: 10.1016/j.bbi.2017.10.021] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
18 Gallily R, Yekhtin Z, Hanuš LO. The Anti-Inflammatory Properties of Terpenoids from Cannabis. Cannabis Cannabinoid Res 2018;3:282-90. [PMID: 30596146 DOI: 10.1089/can.2018.0014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 12.7] [Reference Citation Analysis]
19 Haj CG, Sumariwalla PF, Hanuš L, Kogan NM, Yektin Z, Mechoulam R, Feldmann M, Gallily R. HU-444, a Novel, Potent Anti-Inflammatory, Nonpsychotropic Cannabinoid. J Pharmacol Exp Ther 2015;355:66-75. [PMID: 26272937 DOI: 10.1124/jpet.115.226100] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
20 Atsmon J, Heffetz D, Deutsch L, Deutsch F, Sacks H. Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology. Clinical Pharmacology in Drug Development 2018;7:751-8. [DOI: 10.1002/cpdd.408] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
21 Atsmon J, Cherniakov I, Izgelov D, Hoffman A, Domb AJ, Deutsch L, Deutsch F, Heffetz D, Sacks H. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers. Journal of Pharmaceutical Sciences 2018;107:1423-9. [DOI: 10.1016/j.xphs.2017.12.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
22 Zeng Y, Li Z, Zhu H, Gu Z, Zhang H, Luo K. Recent Advances in Nanomedicines for Multiple Sclerosis Therapy. ACS Appl Bio Mater 2020;3:6571-97. [DOI: 10.1021/acsabm.0c00953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Mechoulam R, Hanuš LO, Pertwee R, Howlett AC. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014;15:757-764. [PMID: 25315390 DOI: 10.1038/nrn3811] [Cited by in Crossref: 169] [Cited by in F6Publishing: 139] [Article Influence: 24.1] [Reference Citation Analysis]
24 Ambrose AF, Verghese T, Dohle C, Russo J. Muscle Overactivity in the Upper Motor Neuron Syndrome. Physical Medicine and Rehabilitation Clinics of North America 2018;29:483-500. [DOI: 10.1016/j.pmr.2018.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Cabral GA, Rogers TJ, Lichtman AH. Turning Over a New Leaf: Cannabinoid and Endocannabinoid Modulation of Immune Function. J Neuroimmune Pharmacol 2015;10:193-203. [PMID: 26054900 DOI: 10.1007/s11481-015-9615-z] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
26 Turri M, Teatini F, Donato F, Zanette G, Tugnoli V, Deotto L, Bonetti B, Squintani G. Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials. Medicines (Basel) 2018;5:E59. [PMID: 29933552 DOI: 10.3390/medicines5030059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
27 Herzog S, Shanahan M, Grimison P, Tran A, Wong N, Lintzeris N, Simes J, Stockler M, Morton RL. Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis. Pharmacoeconomics 2018;36:67-78. [PMID: 28866778 DOI: 10.1007/s40273-017-0565-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
28 Sirikantaramas S, Taura F. Cannabinoids: Biosynthesis and Biotechnological Applications. In: Chandra S, Lata H, Elsohly MA, editors. Cannabis sativa L. - Botany and Biotechnology. Cham: Springer International Publishing; 2017. pp. 183-206. [DOI: 10.1007/978-3-319-54564-6_8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Rabiei Z. Phytotherapy as a Complementary Medicine for Multiple Sclerosis. Turk J Pharm Sci 2019;16:246-51. [PMID: 32454721 DOI: 10.4274/tjps.galenos.2018.90522] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Luquiens A, Lourenco N, Benyamina A, Aubin HJ. Self-medication of achalasia with cannabis, complicated by a cannabis use disorder. World J Gastroenterol 2015;21:6381-3. [PMID: 26034374 DOI: 10.3748/wjg.v21.i20.6381] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Pagano E, Capasso R, Piscitelli F, Romano B, Parisi OA, Finizio S, Lauritano A, Marzo VD, Izzo AA, Borrelli F. An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse. Front Pharmacol. 2016;7:341. [PMID: 27757083 DOI: 10.3389/fphar.2016.00341] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 10.4] [Reference Citation Analysis]
32 Silveira MM, Arnold JC, Laviolette SR, Hillard CJ, Celorrio M, Aymerich MS, Adams WK. Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. Neurosci Biobehav Rev 2017;76:380-95. [PMID: 27639448 DOI: 10.1016/j.neubiorev.2016.09.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
33 Chiarlone A, Börner C, Martín-Gómez L, Jiménez-González A, García-Concejo A, García-Bermejo ML, Lorente M, Blázquez C, García-Taboada E, de Haro A, Martella E, Höllt V, Rodríguez R, Galve-Roperh I, Kraus J, Guzmán M. MicroRNA let-7d is a target of cannabinoid CB1 receptor and controls cannabinoid signaling. Neuropharmacology 2016;108:345-52. [PMID: 27179908 DOI: 10.1016/j.neuropharm.2016.05.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]